Table 3 Univariate analysis of predictive factors for recurrence

From: Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy

 

All patients ( N =88)

HER2 positive ( N =43)

Characteristic

No.

Patients with recurrence (%)

P -value

No.

Patients with recurrence (%)

P -value

Age

 >50 years old

55

10.9

 

28

17.9

 

⩽50 years old

33

18.2

0.28

15

20

0.83

Tumour diameter

 > 50 mm

30

20.0

 

12

25.0

 

 ⩽50 mm

58

10.3

0.22

31

16.1

0.44

Clinical stage

 II

61

9.8

 

30

13.3

 

 III

27

22.2

0.09

13

30.8

0.11

ER or PgR

 Positive

23

13.0

 

9

11.1

 

 Negative

65

13.8

0.87

34

20.6

0.45

HER2

 Positive

43

18.6

    

 Negative

45

9.1

0.19

   

Nuclear grade

 3

61

14.5

 

28

21.4

 

 1–2

26

11.5

0.71

15

13.3

0.49

Type of chemotherapy

 Anthracycline + taxane

81

13.4

 

39

18.0

 

 Taxane based

7

28.6

0.38

4

25.0

0.91

Type of chemotherapy

 With trastuzumab

27

7.4

 

27

7.4

 

 Without trastuzumab

61

16.4

0.28

16

37.5

0.015

Surgery

 Mastectomy

40

12.5

 

21

23.8

 

 BCS

48

14.6

0.84

23

13.6

0.48

Residual DCIS

 Present

39

15.4

 

23

21.7

 

 None

49

12.2

0.65

20

15.0

0.50

No. of LNs examined

 ⩽10

15

14.7

 

7

14.3

 

 >10

73

13.7

0.93

36

19.4

0.79

Axillary LN status

 Node positive

15

46.7

 

6

83.3

 

 Node negative

73

6.9

<0.001

37

8.1

<0.001

  1. Abbreviations: ER=oestrogen receptor; PgR=progesterone receptor; HER2=human epidermal growth factor receptor 2; pCR=pathological complete response; BCS=breast-conserving surgery; DCIS=ductal carcinoma in situ; LN=lymph node.
Back to article page